Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.


Analysts | Earnings Estimates
Bank of America Merrill LynchDerik de Bruin646-855-3100
Barclays CapitalJack Meehan212-526-3909
Credit SuisseErin Wilson Wright212-538-4080
Evercore ISIRoss Muken212-653-9023
Goldman SachsRobert Jones212-357-3336
J.P. MorganTycho Peterson212-622-6568
JefferiesDavid  Windley 615-963-8313
KeyBanc Capital MarketsDonald Hooker917-368-2378
Leerink PartnersJohn Sullivan617-918-4875
Morgan StanleyRicky Goldwasser212-761-4097
MorningstarKelsey Tsai312-384-4985
MUFG Securities Americas Inc.Jason Twizell212-405-7160
Raymond JamesMichael Baker727-567-2499
RBC Capital MarketsGeorge Hill212-618-5585
Robert W. BairdEric Coldwell312-609-5467
SunTrust Robinson HumphreySandy Draper404-926-5273
UBSDaniel Brennan212-713-2317
William BlairJohn Kreger312-364-8597
Charles River Laboratories International, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Charles River Laboratories International, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Charles River Laboratories International, Inc. or its management. Charles River Laboratories International, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Stock Quote

CRL (common)
Change (%)
- 0.24 (0.20%)
Data as of 12/18/18 4:02 p.m. ET
Data provided by Nasdaq.
Minimum 15 minutes delayed.

Refresh Quote

Investor Hotline

877-567-6CRL (6275)